FDA Accepts Cogent Biosciences' NDA for Bezuclastinib in NonAdvSM, Sets December 2026 PDUFA Date
COGT has more than doubled off its 52-week low of $3.72.
Summary
The FDA has accepted Cogent Biosciences' New Drug Application (NDA) for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM), assigning a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2026. Crucially, the FDA has indicated no plans for an advisory committee meeting and has not identified any potential review issues at this time. This acceptance is based on positive clinical results from the pivotal SUMMIT trial. This is a significant de-risking event for Cogent Biosciences, as FDA acceptance of an NDA moves its lead candidate substantially closer to potential market approval. The clear PDUFA date and lack of immediate red flags reduce regulatory uncertainty, which is a material positive for the company. Investors will now closely monitor the PDUFA date for the final regulatory decision, while also anticipating upcoming NDA submissions for bezuclastinib in GIST and Advanced Systemic Mastocytosis (AdvSM) in the coming months.
At the time of this announcement, COGT was trading at $34.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $3.72 to $43.73. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.